Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$5.77
+2.9%
$6.49
$5.20
$15.60
$10.75M0.9211,177 shs23,736 shs
CZX
Canada Zinc Metals
C$0.31
+∞
C$0.31
C$0.22
C$0.39
C$51.69MN/A238,645 shs118,500 shs
First Capital Realty Inc. stock logo
FCR
First Capital Realty
C$0.00
C$18.60
C$22.79
N/AN/A468,009 shs3.04 million shs
MUS
BlackRock MuniHoldings Quality Fund
$13.01
$13.10
$9.20
$13.80
N/AN/A24,765 shs25,224 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
+2.85%+3.04%-6.03%-24.67%-61.53%
CZX
Canada Zinc Metals
0.00%0.00%0.00%0.00%0.00%
First Capital Realty Inc. stock logo
FCR
First Capital Realty
0.00%0.00%0.00%0.00%0.00%
MUS
BlackRock MuniHoldings Quality Fund
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
3.0551 of 5 stars
3.23.00.00.03.31.71.3
CZX
Canada Zinc Metals
N/AN/AN/AN/AN/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/AN/AN/AN/AN/AN/A
MUS
BlackRock MuniHoldings Quality Fund
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
2.33
Hold$50.00766.55% Upside
CZX
Canada Zinc Metals
0.00
N/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
4.00
Strong BuyN/AN/A
MUS
BlackRock MuniHoldings Quality Fund
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MUS, BOLT, CZX, and FCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$80.00
5/13/2025
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$25.00 ➝ $20.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$7.69M1.44N/AN/A$29.89 per share0.19
CZX
Canada Zinc Metals
N/AN/AN/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/AN/AN/AN/A
MUS
BlackRock MuniHoldings Quality Fund
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$63.12M-$33.40N/AN/AN/A-665.56%-94.51%-59.07%8/12/2025 (Estimated)
CZX
Canada Zinc Metals
N/AN/A0.00N/AN/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/A0.00N/AN/AN/AN/AN/AN/A
MUS
BlackRock MuniHoldings Quality Fund
N/AN/A0.00N/AN/AN/AN/AN/A

Latest MUS, BOLT, CZX, and FCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$6.80-$5.80+$1.00-$0.29$0.77 million$1.22 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
N/AN/AN/AN/AN/A
CZX
Canada Zinc Metals
N/AN/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/AN/AN/A
MUS
BlackRock MuniHoldings Quality Fund
$0.614.69%N/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
0.48
3.13
3.13
CZX
Canada Zinc Metals
N/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/A
MUS
BlackRock MuniHoldings Quality Fund
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
901.92 million1.33 millionNot Optionable
CZX
Canada Zinc Metals
147,000166.73 millionN/ANot Optionable
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/ANot Optionable
MUS
BlackRock MuniHoldings Quality Fund
N/AN/AN/ANot Optionable

Recent News About These Companies

BlackRock MuniHoldings NY Quality Closed Fund
BlackRock MuniHoldings NJ Qty
BlackRock Multi-Asset Income Fund Q2 2024 Commentary
MUJ - BlackRock MuniHoldings New Jersey Quality Fund, Inc.
Mums for Memory Fundraiser Ready for Fall
The queen, as imagined — from punk rock to mystery novels
West Dundee awards grants to three restaurants

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bolt Biotherapeutics stock logo

Bolt Biotherapeutics NASDAQ:BOLT

$5.77 +0.16 (+2.85%)
As of 06/30/2025 03:58 PM Eastern

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Canada Zinc Metals CVE:CZX

C$0.31 +0.31 (+∞)
As of 05/4/2018

Canada Zinc Metals Corp. explores for and evaluates mineral resource properties in Canada. The company primarily explores for zinc-lead-silver base metals deposits. Its flagship property is the Akie property that consists of 46 mineral claims, which cover approximately 116 square kilometers, located in the Paleozoic Selwyn Basin, British Columbia. The company was formerly known as Mantle Resources Inc. and changed its name to Canada Zinc Metals Corp. in September 2008. Canada Zinc Metals Corp. was incorporated in 1988 and is headquartered in Vancouver, Canada.

BlackRock MuniHoldings Quality Fund NYSE:MUS

BlackRock MuniHoldings Quality Fund, Inc. is a closed ended fixed income mutual fund launched by BlackRock, Inc. The fund is managed by BlackRock Advisors, LLC. It invests in fixed income markets. The fund invests primarily in portfolios of long-term, investment grade municipal obligations on which the interest is exempt from federal income taxes. It invests principally in municipal bonds that are covered by insurance. BlackRock MuniHoldings Quality Fund, Inc. was formed on May 1, 1998 and is domiciled in United States.